The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours 1,2 . The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity 3-5 . Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity. Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clinical development. In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumours and improved the anti-tumour efficacy of chemotherapy and targeted agents. In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumour microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors. Cured mice rejected the growth of isogenic KRAS G12D tumours, which suggests adaptive immunity against shared antigens. Furthermore, in clinical trials, AMG 510 demonstrated anti-tumour activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mapping of these same residues onto the x-ray crystallographic structure of sotorasib bound to the KRASG12C protein (6OIM)6 suggested strong interactions of R68 and Y96 with sotorasib but probably weaker interactions with the H95 residue, although additional studies would be needed to quantify the strength of these interactions”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [6]
In the citing paper
“Despite the clinical benefit that was observed for many patients treated with KRASG12C inhibitors, acquired resistance to single-agent therapy eventually occurred in most patients.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [6]
In the citing paper
“The mechanisms of acquired resistance to these therapies are currently unknown.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [6]
In the citing paper
“In early-phase clinical trials, two potent, selective, and irreversible small-molecule KRASG12C inhibitors have shown promising results in non–small-cell lung cancer (NSCLC) and more modest efficacy in colorectal cancer: adagrasib (MRTX849) and sotorasib (AMG510).6,7,10”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [6]
In the citing paper
“compounds have been identified that bind covalently to cysteine 12 within the switch II pocket of the GDP-bound form of the KRASG12C protein, preventing oncogenic signaling and causing potent tumor regressions in preclinical models.3-7”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [6]
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A., Yamaizumi, Z., Nishimura, S., & Kim, S.-H. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,059
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citation
Metadata
- Authors
- Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., Lanman, B. A., Werner, J., Rapaport, A. S., San Miguel, T., Ortiz, R., Osgood, T., Sun, J.-R., Zhu, X., McCarter, J. D., Volak, L. P., Houk, B. E., Fakih, M. G., O’Neil, B. H., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Hong, D. S., Ouyang, W., Henary, H., Arvedson, T., Cee, V. J., & Lipford, J. R.
- Affiliations
- Amgen (United States) (US)
- City Of Hope National Medical Center (US)
- Indiana University School of Medicine (US)
- Queen Elizabeth Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Washington University in St. Louis (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Canon, Jude
- Lipford, J. Russell
- ORCID
- Canon, Jude
- Rex, Karen
- Saiki, Anne Y.
- Cooke, Keegan
- Bagal, Dhanashri
- Knutson, Charles G.
- Lanman, Brian A.
- Werner, Jonathan
- Ortiz, Roberto
- Osgood, Tao
- Volak, Laurie P.
- Houk, Brett E.
- Fakih, Marwan G.
- O’Neil, Bert H.
- Price, Timothy J.
- Falchook, Gerald S.
- Desai, Jayesh
- Kuo, James
- Govindan, Ramaswamy
- Hong, David S.
- Ouyang, Wenjun
- Arvedson, Tara
- Cee, Victor J.
- Venue
- Nature
- Published
- 2019-10-30
- Volume
- 575
- Issue
- 7781
- Pages
- 217-223
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2982321167
- Cited by
- 2,277
- References
- 34
- Citations by year
- 2026: 260 · 2025: 324 · 2024: 318 · 2023: 352 · 2022: 361 · 2021: 382 · 2020: 266 · 2019: 10
- FWCI
- 85.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (1s10od021832-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C, sotorasib, KRAS inhibitors, covalent inhibitors, antitumor immunity, tumor microenvironment, immune checkpoint inhibitors, adaptive immunity, KRAS G12D, tumor regression, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Drug Synergism, Humans, Immunotherapy, Inflammation, Lung Neoplasms, Phosphorylation, Piperazines, Pyridines, Pyrimidines, Signal Transduction, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. https://app.cochat.ai/papers/10.1038/s41586-019-1694-1
- The paper
- Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., Lanman, B. A., Werner, J., Rapaport, A. S., San Miguel, T., Ortiz, R., Osgood, T., Sun, J.-R., Zhu, X., McCarter, J. D., . . . Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. https://doi.org/10.1038/s41586-019-1694-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.